Lynx1 Capital Management
Latest statistics and disclosures from Lynx1 Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are GHRS, CGEM, STOK, AGIO, CCCC, and represent 93.88% of Lynx1 Capital Management's stock portfolio.
- Added to shares of these 10 stocks: GHRS (+$67M), AGIO (+$30M), PLRX, CCCC, PRQR, TRAW, FHTX, PASG, AVTX, NUVB.
- Started 6 new stock positions in IKT, FHTX, AVTX, EPRX, NUVB, PLRX.
- Reduced shares in these 9 stocks: DNLI (-$48M), STOK (-$24M), XNCR (-$8.3M), IMTX, DSGN, DTIL, TRDA, IBIO, CGON.
- Sold out of its positions in DSGN, IBIO.
- Lynx1 Capital Management was a net buyer of stock by $19M.
- Lynx1 Capital Management has $866M in assets under management (AUM), dropping by 36.80%.
- Central Index Key (CIK): 0001910456
Tip: Access up to 7 years of quarterly data
Positions held by Lynx1 Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Lynx1 Capital Management
Lynx1 Capital Management holds 27 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Gh Research Ordinary Shares (GHRS) | 41.2 | $357M | +23% | 13M | 26.88 |
|
| Cullinan Oncology (CGEM) | 18.9 | $163M | 9.0M | 18.21 |
|
|
| Stoke Therapeutics (STOK) | 15.3 | $132M | -15% | 4.0M | 32.72 |
|
| Agios Pharmaceuticals (AGIO) | 14.6 | $127M | +30% | 3.4M | 37.11 |
|
| C4 Therapeutics Com Stk (CCCC) | 4.0 | $34M | +4% | 7.3M | 4.67 |
|
| Korro Bio (KRRO) | 2.3 | $20M | 1.5M | 13.18 |
|
|
| Tscan Therapeutics (TCRX) | 0.9 | $7.9M | 8.0M | 0.98 |
|
|
| Precision Biosciences Com New (DTIL) | 0.9 | $7.5M | -3% | 951k | 7.86 |
|
| Neuphoria Therapeutics (NEUP) | 0.4 | $3.8M | 875k | 4.37 |
|
|
| Passage Bio Com New (PASG) | 0.4 | $3.3M | +8% | 674k | 4.88 |
|
| Cg Oncology (CGON) | 0.3 | $2.2M | 31k | 71.05 |
|
|
| Pliant Therapeutics (PLRX) | 0.2 | $2.0M | NEW | 1.8M | 1.14 |
|
| Entrada Therapeutics (TRDA) | 0.2 | $1.3M | -15% | 179k | 7.36 |
|
| Vyne Therapeutics (VYNE) | 0.1 | $1.1M | 1.6M | 0.65 |
|
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.1 | $970k | +661% | 521k | 1.86 |
|
| Traws Pharma Com New (TRAW) | 0.1 | $472k | +3610% | 560k | 0.84 |
|
| Foghorn Therapeutics (FHTX) | 0.0 | $301k | NEW | 62k | 4.88 |
|
| Denali Therapeutics (DNLI) | 0.0 | $300k | -99% | 12k | 25.72 |
|
| Xencor (XNCR) | 0.0 | $293k | -96% | 18k | 16.10 |
|
| Absci Corp (ABSI) | 0.0 | $246k | 21k | 11.59 |
|
|
| Werewolf Therapeutics (HOWL) | 0.0 | $237k | 658k | 0.36 |
|
|
| Immatics SHS (IMTX) | 0.0 | $235k | -89% | 23k | 10.13 |
|
| Avalo Therapeutics Com New (AVTX) | 0.0 | $187k | NEW | 10k | 18.48 |
|
| Bolt Biotherapeutics Com New (BOLT) | 0.0 | $119k | 31k | 3.85 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 0.0 | $91k | NEW | 16k | 5.68 |
|
| Eupraxia Pharmaceuticals (EPRX) | 0.0 | $66k | NEW | 10k | 6.61 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.0 | $41k | NEW | 20k | 2.03 |
|
Past Filings by Lynx1 Capital Management
SEC 13F filings are viewable for Lynx1 Capital Management going back to 2021
- Lynx1 Capital Management 2026 Q2 restated filed Aug. 13, 2026
- Lynx1 Capital Management 2026 Q2 filed Aug. 12, 2026
- Lynx1 Capital Management 2026 Q1 filed May 4, 2026
- Lynx1 Capital Management 2025 Q4 filed Feb. 17, 2026
- Lynx1 Capital Management 2025 Q3 filed Nov. 13, 2025
- Lynx1 Capital Management 2025 Q2 filed Aug. 14, 2025
- Lynx1 Capital Management 2025 Q1 filed May 15, 2025
- Lynx1 Capital Management 2024 Q4 filed Feb. 14, 2025
- Lynx1 Capital Management 2024 Q3 filed Nov. 14, 2024
- Lynx1 Capital Management 2024 Q2 amended filed Aug. 19, 2024
- Lynx1 Capital Management 2024 Q2 filed Aug. 14, 2024
- Lynx1 Capital Management 2024 Q1 amended filed May 30, 2024
- Lynx1 Capital Management 2024 Q1 filed May 15, 2024
- Lynx1 Capital Management 2023 Q4 filed Feb. 14, 2024
- Lynx1 Capital Management 2023 Q3 filed Nov. 14, 2023
- Lynx1 Capital Management 2023 Q2 filed Aug. 14, 2023